These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25077556)

  • 1. LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma.
    Tsai TH; Wang M; Di Poto C; Hu Y; Zhou S; Zhao Y; Varghese RS; Luo Y; Tadesse MG; Ziada DH; Desai CS; Shetty K; Mechref Y; Ressom HW
    J Proteome Res; 2014 Nov; 13(11):4859-68. PubMed ID: 25077556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients.
    Huang Y; Zhou S; Zhu J; Lubman DM; Mechref Y
    Electrophoresis; 2017 Sep; 38(17):2160-2167. PubMed ID: 28543513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESI-LC-MS Method for Haptoglobin Fucosylation Analysis in Hepatocellular Carcinoma and Liver Cirrhosis.
    Zhang Y; Zhu J; Yin H; Marrero J; Zhang XX; Lubman DM
    J Proteome Res; 2015 Dec; 14(12):5388-95. PubMed ID: 26503433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of hepatocellular carcinoma using glycomic analysis.
    Goldman R; Ressom HW; Varghese RS; Goldman L; Bascug G; Loffredo CA; Abdel-Hamid M; Gouda I; Ezzat S; Kyselova Z; Mechref Y; Novotny MV
    Clin Cancer Res; 2009 Mar; 15(5):1808-13. PubMed ID: 19223512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus.
    Cong M; Ou X; Huang J; Long J; Li T; Liu X; Wang Y; Wu X; Zhou J; Sun Y; Shang Q; Chen G; Ma H; Xie W; Piao H; Yang Y; Gao Z; Xu X; Tan Z; Chen C; Zeng N; Wu S; Kong Y; Liu T; Wang P; You H; Jia J; Zhuang H
    OMICS; 2020 Jul; 24(7):415-423. PubMed ID: 32522092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Potential Serum
    Higashi M; Yoshimura T; Usui N; Kano Y; Deguchi A; Tanabe K; Uchimura Y; Kuriyama S; Suzuki Y; Masaki T; Ikenaka K
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of MALDI-TOF mass spectrometry data for detection of glycan biomarkers.
    Ressom HW; Varghese RS; Goldman L; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Goldman R
    Pac Symp Biocomput; 2008; ():216-27. PubMed ID: 18229688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies.
    Zhu J; Lin Z; Wu J; Yin H; Dai J; Feng Z; Marrero J; Lubman DM
    J Proteome Res; 2014 Jun; 13(6):2986-97. PubMed ID: 24807840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.
    Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K
    Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS.
    Kang X; Sun L; Guo K; Shu H; Yao J; Qin X; Liu Y
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1151-9. PubMed ID: 20130913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma.
    Ressom HW; Varghese RS; Goldman L; An Y; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Drake SK; Goldman R
    J Proteome Res; 2008 Feb; 7(2):603-10. PubMed ID: 18189345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated annotation and quantitation of glycans by liquid chromatography/electrospray ionization mass spectrometric analysis using the MultiGlycan-ESI computational tool.
    Hu Y; Zhou S; Yu CY; Tang H; Mechref Y
    Rapid Commun Mass Spectrom; 2015 Jan; 29(1):135-42. PubMed ID: 25462374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches.
    Zhu J; Warner E; Parikh ND; Lubman DM
    Mass Spectrom Rev; 2019 May; 38(3):265-290. PubMed ID: 30472795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.
    Bowers J; Hughes E; Skill N; Maluccio M; Raftery D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():154-62. PubMed ID: 24666728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative glycomic profiling of isotopically permethylated N-glycans by liquid chromatography/electrospray ionization mass spectrometry.
    Hu Y; Desantos-Garcia JL; Mechref Y
    Rapid Commun Mass Spectrom; 2013 Apr; 27(8):865-77. PubMed ID: 23495056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outer arm fucosylation of N-glycans increases in sera of hepatocellular carcinoma patients.
    Tanabe K; Deguchi A; Higashi M; Usuki H; Suzuki Y; Uchimura Y; Kuriyama S; Ikenaka K
    Biochem Biophys Res Commun; 2008 Sep; 374(2):219-25. PubMed ID: 18619944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.